Toll-Like Receptor 9 Stimulation Induces Aberrant Expression of a Proliferation-Inducing Ligand by Tonsillar Germinal Center B Cells in IgA Nephropathy

Masahiro Muto,* Benoit Manfroi,† Hitoshi Suzuki,* Kensuke Joh,‡ Masaaki Nagai,§ Sachiko Wakai,† Christian Righini,¶ Masayuki Maiguma,* Shozo Izui,** Yasuhiko Tomino,* Bertrand Huard,† and Yusuke Suzuki*

*Division of Nephrology, Department of Internal Medicine, Juntendo University, Tokyo, Japan; †Analytical Immunology for Chronic Pathologies, Albert Bonniot Institute, Institut National de la Santé et de la Recherche Médicale/University Joseph Fourier U823, Grenoble, France; ‡Department of Pathology, Tohoku University Graduate School of Medicine, Sendai, Japan; §Division of Nephrology and Diabetology, Narita Memorial Hospital, Toyohashi, Japan; ¶Department of Otolaryngology, Head and Neck Surgery, Grenoble University Hospital, Grenoble, France; and **Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland

ABSTRACT

The TNF family member a proliferation-inducing ligand (APRIL; also known as TNFSF13), produced by myeloid cells, participates in the generation and survival of antibody-producing plasma cells. We studied the potential role of APRIL in the pathogenesis of IgA nephropathy (IgAN). We found that a significant proportion of germinal centers (GCs) in tonsils of patients with IgAN contained cells aberrantly producing APRIL, contributing to an overall upregulation of tonsillar APRIL expression compared with that in tonsils of control patients with tonsillitis. In IgAN GC, antigen-experienced IgD⁺CD38⁺CD19⁺ B cells expressing a switched IgG/IgA B cell receptor produced APRIL. Notably, these GC B cells expressed mRNA encoding the common cleavable APRIL-α but also, the less frequent APRIL-δ/ζ mRNA, which encodes a protein that lacks a furin cleavage site and is, thus, the uncleavable membrane-bound form. Significant correlation between TLR9 and APRIL expression levels existed in tonsils from patients with IgAN. In vitro, repeated TLR9 stimulation induced APRIL expression in tonsillar B cells from control patients with tonsillitis. Clinically, aberrant APRIL expression in tonsillar GC correlated with greater proteinuria, and patients with IgAN and aberrant APRIL overexpression in tonsillar GC responded well to tonsillectomy, with parallel decreases in serum levels of galactose-deficient IgA1. Taken together, our data indicate that antibody disorders in IgAN associate with TLR9-induced aberrant expression of APRIL in tonsillar GC B cells.


IgA nephropathy (IgAN) is the most common form of GN, accounting for 25%–50% of patients with primary GN. Accumulating evidence now suggests that 30%–40% of patients with IgAN progress to ESRD within 20 years from the estimated time of disease onset.1,2 The lack of comprehensive understanding of IgAN development impairs the design of a specific treatment for this disease. The pathogenesis of IgAN may be associated with systemic immune dysregulation from a mucosa-bone marrow axis rather than an abnormality intrinsic to the
renal resident cells. At the mucosal level, infections, particularly in the upper respiratory tract, exacerbate clinical manifestations in patients with IgAN. Recent studies report that aberrantly O-glycosylated IgA1 (i.e., galactose-deficient [Gd] IgA1) and the subsequently formed IgA immune complexes (ICs) with glycan-specific autoantibodies are pivotal to the development of IgAN.

A proliferation-inducing ligand (APRIL) is a member of the TNF superfamily of ligands expressed as a type 2 transmembrane protein. APRIL is usually cleaved in the Golgi apparatus by a furin convertase and then, secreted as a soluble ligand. Myeloid and mucosal epithelial cells produced APRIL. APRIL binds to two members of the TNF receptor family: the B cell maturation antigen (BCMA) and the transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). Functionally, APRIL mediates class switch, mostly for IgA. APRIL is also crucial for long-term survival of plasma cells in the bone marrow and mucosa. Recently, high serum level of APRIL in patients with IgAN correlating with urinary proteins was reported. In addition, a genome-wide association study of patients with IgAN suggested APRIL (TNFSF13) to be a susceptibility gene. However, the cellular source of APRIL production and the pathway by which this molecule is upregulated in IgAN remain ill defined.

Toll-like receptors (TLRs) are a family of germline-encoded receptors that recognize adjuvant conserved molecular motifs commonly found in microbial pathogens. TLR9 recognizes unmethylated DNA sequences in bacterial and viral DNA and is involved in innate immune responses by providing protective immune responses against invading viral and bacterial pathogens. Although TLR9 has been shown to be implicated in the development of kidney diseases, including IgAN, the mechanisms by which TLR9 activation contributes to the development of IgAN are poorly understood.

RESULTS

Upregulation of APRIL Expression in Tonsillar Germinal Center of Patients with IgAN

Real-time quantitative PCR (qPCR) analyses in patients with IgAN (n=24) and patients with chronic tonsillitis (CT; n=6) revealed that tonsillar APRIL mRNA expression was significantly higher in IgAN than in CT (Figure 1A) (P<0.01).
Immunohistochemistry with Stalk-1, an anti-APRIL antibody that detects APRIL-producing cells, further showed that APRIL-producing cells were present in the tonsillar epithelium and outside in cells identified as neutrophils in both patients with IgAN (n=55) and patients with CT (n=12) (Figure 1B), consistent with our previous report in patients with CT.11 Stalk-1 and elastase (neutrophil-specific) costaining did not reveal a difference in the number of infiltrating neutrophils between patients with IgAN and patients with CT (Figure 1C). The epithelial staining by Stalk-1 was also not different. One obvious difference was the presence of a substantial number of Stalk-1+ APRIL–producing cells in germinal centers (GCs) in patients with IgAN. We observed that the percentage of Stalk-1+GC (27.4%±21.3%) in patients with IgAN was significantly higher than that in patients with CT (7.2%±6.8%; P<0.01) (Figure 1D).

Ig–Switched GC B Cells Produce APRIL in Tonsils of Patients with IgAN

Stalk-1+ cells in tonsillar GCs of patients with IgAN expressed CD19, identifying them as B cells (Figure 2A). We further observed that Stalk-1+ APRIL–producing cells in tonsillar GCs had a nonswitched IgM and switched IgG or IgA phenotypes. Flow cytometric analyses revealed that the Stalk-1+ CD19+ cell population had lost IgD surface expression and variably expressed the GC activation marker CD38 in patients with IgAN (n=13) (Figure 2B, top panel). We also detected this Stalk-1+ GC B cell population in CT (n=4) (Figure 2B, middle panel), but this cell population was clearly increased in some patients with IgAN (Figure 2B, bottom panel) (P<0.05).

GC B Cells Express an Uncleavable Form of APRIL in Patients with IgAN

The Stalk-1 staining pattern obtained in GC B cells from patients with IgAN was clearly different from the one in PMN cells described previously11 (Figure 3A). We additionally performed immunohistochemical analysis with Aprily-2 antibody, which recognizes the secreted part of APRIL.29 We observed that the Aprily-2 staining colocalized with Stalk-1 in tonsillar GCs from patients with IgAN (Figure 3B). Such colocalization of Stalk-1 and Aprily-2 has never been observed in healthy and pathologic tissues.30 A recent study reported a possible expression of APRIL-δ and -ζ, APRIL isoforms lacking the consensus motif for the furin convertase, in B cell precursor acute lymphoblastic leukemia,31 and such isoforms could be stained with both Stalk-1 and Aprily-2. RT-PCR analyses revealed that...
tonsillar B cells from patients with IgAN and patients with CT indeed expressed APRIL-δ and -ζ in addition to the common furin-cleavable APRIL-α (Figure 3C). Real-time qPCR further showed that the abundances of APRIL-α and APRIL-δ/ζ mRNA in tonsillar B cells of patients with IgAN were significantly higher than those in patients with CT (Figure 3D).

**TLR9 Stimulation Induces APRIL Expression in GC B Cells**

Levels of TLR9 mRNA in whole tonsils and tonsillar B cells of patients with IgAN were significantly higher than those of patients with CT (Figure 4A), and an increase of TLR9 mRNA well correlated with an increase of APRIL-α and APRIL-δ/ζ mRNA in tonsillar B cells of patients with IgAN (Figure 4B).

We next stimulated whole tonsillar cells from patients with CT with the TLR9 ligand CpG-oligodeoxynucleotide (CpG-ODN) and analyzed APRIL expression on CD19+ B cells. A daily stimulation induced a reactivity of CD19+ cells with Stalk-1 and Aprily-2 antibodies starting at day 3, with a maximum seen at day 7, in CD19+ cells (Figure 5A). The APRIL reactivity was observed intracellularly with a limited signal at the cells surface. The weak surface APRIL expression on CpG-stimulated B cells was consistent with the absence of surface staining observed ex vivo. Repeated TLR9 stimulation weakly but clearly upregulated expression of the APRIL receptors TACI and BCMA as well (Figure 5B). Consistent with analyses in Figure 5A, the same APRIL reactivities were observed in studies with purified tonsillar B cells at day 7 (Figure 5C). Taken together, these indicate a putative autocrine APRIL signaling in CpG-stimulated B cells.

**APRIL Expression in Tonsillar GC Is Associated with the Severity of IgAN and Treatment Responses to Tonsillectomy**

We assessed whether the extent of Stalk-1+ GC in tonsils may affect the severity of IgAN and therapeutic responses to tonsillectomy. The percentage of Stalk-1+GC was significantly higher in patients with IgAN with an elevated proteinuria (Figure 6A)
**DISCUSSION**

Mucosal immune dysregulation has already been reported in the pathogenesis of IgAN. However, the underlying mechanism remains unclear. APRIL and B cell–activating factor belonging to the TNF family derived from myeloid cells, such as neutrophils, monocytes, and dendritic cells, are TNF superfamily members best known for their roles in the survival and maturation of B cells. Recent studies revealed that mature B cell neoplasms, including chronic lymphocytic leukemia, follicular lymphoma, and diffuse large B cell lymphoma, may start to produce APRIL by themselves. This aberrant production of APRIL was also observed in B cells from patients suffering from autoimmune diseases, such as SLE. In fact, repeated stimulation of B cells induced their expression of APRIL. This study shows, for the first time, an aberrant upregulation of APRIL in tonsillar GC B cells from patients with IgAN.

In GC B cells from IgAN, we observed that the reactivity of the two APRIL-specific antibodies, Stalk-1 and Aprily-2, was clearly different from the one obtained in other organs. Indeed, we observed an uncommon co-staining of Stalk-1 and Aprily-2, revealing the presence of a full-length form of APRIL. The detection of the two furin uncleavable isoforms of APRIL, APRIL-δ and -ζ mRNA, is consistent with this observation. This uncleavable full-length APRIL was detected intracellularly and most likely stored in vesicles, warranting further investigations (Figure 3A).

Exacerbation of IgAN on upper respiratory infections allows speculation on the participation of exogenous antigens in disease progression. The palatine tonsils have a unique cellular composition in the reticulated subepithelium, which is ideal for productive antigen sampling for rapid and broad defense against microorganisms at the gate of the respiratory and digestive tracts. Transient mucosal activation of a pattern recognition receptor, such as TLR, by pathogen-associated molecular patterns in IgAN-prone mice is sufficient to exacerbate this disease, with rapid serum elevation of IgA and ICs. We recently showed that tonsillar levels of TLR9 expression but not those of other TLRs were associated with the disease activity of IgAN and clinical outcome of tonsilllectomy. Furthermore, the TLR9 genotype was strongly associated with histologic severity of IgAN. Genome-wide scan identifies a copy number variable region at 3p21.1 that in this disease, with rapid serum elevation of IgA and ICs.

**Figure 4.** Correlation between TLR9 and APRIL mRNA expressions in patients with IgAN. (A) TLR9 mRNA expressions in whole tonsils (left panel) and purified tonsillar B cells (right panel) were significantly higher in IgAN. Bars represent the mean±SEM. *P<0.01; **P<0.05. (B) TLR9 and APRIL-α (left panel) or -ζ (right panel) mRNA expressions in tonsillar B cells were well correlated in patients with IgAN.
receptors BCMA and TACI on B cells and enhanced B cell activation and Ig secretion.\textsuperscript{38,39} We are reporting here that chronic CpG-ODN stimulation induced APRIL production by tonsillar B cells. The findings of this study provide a rationale for tonsillectomy and indicate that the TLR9-APRIL axis is a promising specific target for future treatment apart from nonspecific immunosuppressants or tonsillectomy. Also, although the possible contribution of specific exogenous antigens to the pathogenesis of IgAN, including \textit{Haemophilus parainfluenzae}, has been discussed,\textsuperscript{40} there are no consistent antigens yet. Our previous and recent studies regarding the involvement of TLR9 in the pathogenesis of human and murine IgAN indicate that specific antigens are not required for the development of IgAN. However, it seems that there is a biased bacterial flora in tonsil of human IgAN,\textsuperscript{41} suggesting that actual exogenous antigens in the pathogenesis may be limited.

We observed that tonsillar levels of APRIL correlated with disease activity and treatment responses to tonsillectomy, indicating that tonsillar GC B cells may be involved in the pathogenesis via their production of APRIL. It is now widely accepted that Gd-IgA1 and related ICs are essential effector molecules to induce glomerular damages in IgAN.\textsuperscript{7,42} Serum levels of these molecules, indeed, have clinical diagnostic potential for the assessment of prognosis and disease activity for IgAN, independent of information from renal biopsy.\textsuperscript{42–45} Reports showed abnormal glycosylation of tonsillar IgA\textsuperscript{46,47} and aberrant cytokine profiles in tonsillar B cells, leading to the underglycosylation of IgA1 in patients with IgAN.\textsuperscript{48–51} Because total IgA is decreased by approximately 10% on average after tonsillectomy alone in patients with IgAN\textsuperscript{27} and because patients who showed a large decrease of serum IgA after the tonsillectomy had better clinical outcome, the palatine tonsil was hypothesized to be a major delivery source of nephritogenic IgA.\textsuperscript{27,26} Indeed, we recently showed that Gd-IgA1 was significantly decreased after tonsillectomy in patients with IgAN, who also showed a significant improvement in urinalysis just after tonsillectomy.\textsuperscript{56} This study further showed that
patients with IgAN with abundant expression of Stalk-1 in tonsillar GC showed more proteinuria and better clinical outcomes after the tonsillectomy, including improvement of proteinuria and decrease of serum Gd-IgA1 levels. These findings suggest that palatine tonsils with overexpression of APRIL may be one of the major delivery source of nephritogenic IgA. However, some patients notably showed improved hematuria and serum Gd-IgA1 levels after steroid pulse therapy after the tonsillectomy compared with just after tonsillectomy, suggesting that Gd-IgA1–producing cells may also be localized outside the tonsils.26 Recent data have revealed that some of the NALT–derived and activated B cells and even tonsillar B cells can migrate from inductive mucosal sites to systemic effector sites, including bone marrow, through guiding adhesion molecules and chemokine/chemokine receptors.52,53 In addition, our recent study revealed that IgA secreted by Epstein–Barr virus–immortalized dBc cells from the peripheral blood of patients with IgAN was mostly polymeric with Gd sialylated O-glycans.54 These findings support the hypothesis that Gd-IgA1–producing B cells may travel between the tonsils and systemic lymphoid organs and produce the nephritogenic IgA outside of mucosal sites. Moreover, bone marrow transplantation with an IgAN donor reconstitutes IgAN in humans and mice,55,56 suggesting that Gd-IgA1–producing B cells could localize in the bone marrow. Indeed, it has been reported that IgA plasma cells containing subclass IgA1 were increased in patients with IgAN compared with controls.57,58 It has also been shown that there was an increase

IgA1 after tonsillectomy than those with Stalk-1**GC<10%. *P<0.05. (E–G) Comparison of proteinuria levels before and after tonsillectomy in (E) patients with IgAN (**P<0.01), (F) those with Stalk-1**GC≥10% (*P<0.01), and (G) those with Stalk-1**GC<10%. There were significant differences before and after tonsillectomy in the preceding two groups, despite no significance in patients with IgAN with Stalk-1**GC<10%. The average duration from tonsillectomy to quantification of these clinical parameters was 69.2±47.2 days.

Figure 6. Correlation between APRIL expression in tonsillar GC and disease activity in patients with IgAN. (A) Percentage of Stalk-1**GC in tonsils of patients with IgAN and their proteinuria level. The percentage of Stalk-1**GC in patients with IgAN with proteinuria >1 g/g creatinine (Cr) was significantly higher than that in those with proteinuria <1 g/g Cr. *P<0.01. (B) Comparison of proteinuria level, (C) percentage decrease of the serum IgA, and (D) the serum Gd-IgA1 levels between patients with IgAN with the percentage of Stalk-1**GC≥10% and those with the percentage of Stalk-1**GC<10%. Patients with IgAN with Stalk-1**GC≥10% showed significantly higher proteinuria before tonsillectomy and larger decrease of serum levels of Gd-
in the proportion of IgA\textsuperscript{+} cells that express J-chain mRNA, which is essential for the production of dimeric IgA, in the bone marrow of patients with IgAN.\textsuperscript{59} These lines of evidence emphasize the possibility that the bone marrow could be the production site of the IgA1 found in the circulation and mesangial deposits in patients with IgAN. Thus, we can speculate that mucosally primed/activated Gd-IgA1–producing B cells are disseminated to systemic organs, such as lymph nodes and tonsils, or the bone marrow.

In conclusion, APRIL\textsuperscript{+}GC B cells in tonsils may determine the disease activity of patients with IgAN, presumably via production of Gd-IgA1 before IC formation. Aberrant TLR9 activation in tonsillar B cells may be involved in the underlying mechanisms of the tonsillar overexpression of APRIL, partly with APRIL variants, in IgAN (Figure 7).

**CONCISE METHODS**

**Patients and Treatment Protocol**

Fifty-five patients with biopsy-proven IgAN (26 men) and 12 patients with CT (six men) who had undergone tonsillectomy at the Department of Otorhinolaryngology of Juntendo University Hospital, Narita Memorial Hospital, or Tokyo Metropolitan Health and Medical Treatment Corporation, Okubo Hospital were included in this study. Patient demographics and clinical characteristics are summarized in Table 1 and Supplemental Table 2. Both before and after tonsillectomy, patients with IgAN were evaluated for the following clinical outcomes: proteinuria (grams per gram creatinine) and serum levels of IgA and Gd-IgA1. The average duration from tonsillectomy to quantification of these clinical parameters was 69.2±47.2 days. This study was conducted in accordance with the principles of the Declaration of Helsinki, and the study protocol was approved by the institutional review board of each hospital. Informed consents were obtained from all patients before inclusion in the study.

**Real-Time Quantitative RT-PCR and Sequencing**

qPCR on RNA isolated from tonsillar tissues and cells was performed as described previously.\textsuperscript{27} A Homo sapiens–specific Taqman gene expression assay (Life Technologies, Carlsbad, CA) was purchased for the TNF (ligand) superfamily, member 13 (APRIL; Hs00601664_g1) and TLR9 (Hs00370913_s1) as well as for an endogenous control, glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Hs99999905_m1).

A SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) and a 7500 Real-Time PCR System (Applied Biosystems) were also used for qPCR for APRIL-α and -β expression. Transcript levels were normalized by GAPDH. The following primers synthesized by Life Technologies were used: APRIL-α, 5'-AGGAGACAGTGCTCACC-C3' and 5'-CTCCGATCTGGATTGCGG-3'; APRIL-β, 5'-AGAGCTCCGGAGGACGAG-3' and 5'-CTCCGATCTGGATTGCGG-3'; and GAPDH, 5'-TGACTCGACCTTCACCTTC-3' and 5'-CTCTGCTCTCTCCTTGGAC-3'.

For sequencing purposes, total RNA from tonsillar B cells was extracted using the QIA Shredder (Qiagen, Valencia, CA) and the exogenous control, glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Hs99999905_m1).

**Figure 7.** Crosstalk between APRIL and TLR9 on B cells in tonsillar GCs of patients with IgAN. This study revealed aberrant APRIL expression in tonsillar GC B cells from patients with IgAN. On the basis of our findings, we hypothesize that activation of intracellular TLR9 through exogenous antigens may be involved in this overexpression consisting of not only APRIL-α but also, uncleaved APRIL, such as APRIL-β/γ in tonsillar GC B cells of patients with IgAN. This TLR9 activation also upregulates expression of TACI and BCMA and increases both BCR signaling and APRIL sensitivity. This aberrant GC B cells of patients with IgAN. This study revealed aberrant APRIL expression in tonsillar GC B cells responsible for the production of aberrant antibodies, including Gd-IgA1, and thereby, contribute to subsequent progression of IgAN.

| Table 1. Profiles of patients with IgAN and CT just before tonsillectomy |
|--------------------------|-----------------|-----------------|
| **Patients profile**     | **IgAN**        | **CT**          |
| n                        | 55              | 12              |
| Age, yr                  | 35.1            | 31.4            |
| Men, %                   | 47.3 (26:29)    | 50 (6:6)        |
| Duration from onset to tonsillectomy, yr | 8.5±8.8        | —               |
| sCr, mg/dl               | 0.86±0.3        | 0.6±0.14        |
| BUN, mg/dl               | 13.1±3.2        | 11.5±3.6        |
| eGFR, ml/min per 1.73 m\textsuperscript{2} | 79.5±28.1      | 116.4±26.7     |
| Proteinuria-to-urine Cr ratio, g/g Cr | 1.22±0.86      | —               |
| Hematuria (RBCs per HPF)  |                  |                 |
| 1–4                      | 8               | —               |
| 5–9                      | 9               | —               |
| 10–15                    | 3               | —               |
| 16–20                    | 11              | —               |
| 21–25                    | 5               | —               |
| 26–30                    | 3               | —               |
| >30                      | 16              | —               |

Values are means±SD. Hematuria was assessed by assigning scores according to the number of red blood cells (RBCs) per high-power field (HPF).

—, not done; sCr, serum creatinine; Cr, creatinine.
Table 2. The correlation between Stalk-1+GC and the severity or the efficacy of tonsillectomy in patients with IgAN

<table>
<thead>
<tr>
<th>Stalk-1+GC&lt;10%, n=12</th>
<th>Stalk-1+GC≥10%, n=43</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proteinuria (g/g creatinine) before treatment</td>
<td>0.69±0.48</td>
<td>1.35±0.9</td>
</tr>
<tr>
<td>Patients whose proteinuria decreased &gt;50% after tonsillectomy, %</td>
<td>25.0 (3 of 12)</td>
<td>62.8 (27 of 43)</td>
</tr>
</tbody>
</table>

ELISA for Gd-IgA1

The serum level of Gd-IgA1 was measured by lectin ELISA using GalNAc-specific lectin from Helix aspersa (HAA; Sigma-Aldrich, St. Louis, MO) as previously reported. The captured IgA was treated with 100 ng per well of serum IgA. The captured IgA was treated with 10 mU/ml neuraminidase (Roche Diagnostics, Indianapolis, IN) to reveal terminal sialic acid residues. The desialylated IgA1 was then treated with biotin-labeled HAA, and subsequently developed absorbance was measured at 490 nm. The HAA reactivity of IgA1 in each sample was then calculated as OD units per 100 ng serum IgA. Naturally Gd-IgA1 (A) myeloma protein was treated with neuraminidase and used as the standard. Serum level of total Gd-IgA1 was expressed in relative units calculated by multiplying the normalized HAA reactivity by the amount of IgA in the serum sample (milligrams per milliliter).

Flow Cytometric Analyses

In total, 1×10^6 tonsillar cells were stained for flow cytometry. The cells were preincubated with Fc receptor blocking reagent (MBL, Aichi, Japan) and incubated for 30 minutes at 4°C with FITC-conjugated mouse anti-human CD19 antibody (BioLegend, San Diego, CA), APC mouse anti-human CD38 (BD Pharmingen, San Jose, CA), and PE mouse anti-human IgD (BD Pharmingen). Biotinylated anti-TACI and BCMA have been previously described. PE-conjugated streptavidin was from BD Pharmingen. Total staining was performed after permeabilization with a Cytofix/Cytoperm Solution (BD Pharmingen) for 30 minutes at 4°C. After washing twice in Perm/Wash solution, cells were incubated for 30 minutes at 4°C with Stalk-1 (5 μg/ml) and Aprily-2 (5 μg/ml). Brilliant Violet 421 donkey anti–rabbit or mouse IgG (BioLegend) was used as secondary antibody. After washing the cells twice in BD Perm/Wash solution, labeled cells were analyzed by flow cytometry using a FACSVerse Flow Cytometer (Becton Dickinson, Franklin Lakes, NJ) and the FlowJo program (TreeStar, Inc., Ashland, OR).
Statistical Analyses

Statistical analyses were performed using GraphPad PRISM software, version 6.0 (GraphPad Software, La Jolla, CA). Comparisons between groups were analyzed by the Mann–Whitney U test. Spearman regression analysis was used to analyze the correlation between two variables. Differences at P<0.05 were considered significant.

ACKNOWLEDGMENTS

The authors thank Drs. Takaaki Oobayashi, Kanae Yoshikawa, and Hiroshi Kitagawa for preparation of tonsillar samples. Technical assistance was provided by Ms. Terumi Shibata, Dr. Masao Kihara, Dr. Akemi Kawasaki, Dr. Takako Ikegami, and Dr. Tomomi Ikeda (Division of Molecular and Biochemical Research, Juntendo University Graduate School of Medicine).

This study was supported by grants-in-aid from the Ministry of Health, Labor and Welfare of Japan (to M. Muto, H.S., M. Maiguma, and Y.S.) and grants from the Japanese Swiss Science and Technology Cooperation Program, the Strategic International Research Cooperative Program, the Japan Science and Technology Agency (to Y.T., B.H., and Y.S.), the Foundation Finovi (to B.H.), and Joseph Fourier University (to B.H.).

DISCLOSURES

None.

REFERENCES


the bone marrow as the source of mesangial IgA. Am J Kidney Dis 12: 410–414, 1988

This article contains supplemental material online at http://jasn.asnjournals.org/lookup/suppl/doi:10.1681/ASN.2016050496/-/DCSupplemental.